Wary pharma: AstraZeneca sours on UK

This podcast episode from The Economist covers three main topics: the potential shift of AstraZeneca's primary listing to New York due to concerns about the commercial environment in the UK, the Royal Navy's integration of drones into its air wing, and the efforts to restore coral reefs in Colombia following hurricane damage. The discussion on AstraZeneca explores the reasons behind the company's concerns, including clawback taxes and drug approval processes, while also acknowledging the UK's strengths in scientific talent and research. The segment on naval aviation discusses the advantages and challenges of incorporating drones into naval operations, including cost-effectiveness and ethical considerations. Finally, the episode highlights a successful coral restoration project in Colombia, focusing on innovative techniques and the involvement of local communities.